A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of continuing vorinostat (MK-0683)
dosing in cancer patients previously enrolled in one of five base studies (MK-0683-001,
MK-0683-006, MK-0683-008, MK-0683-012, or MK-0683-013) who have shown benefit from receiving
this drug.